A strong synergy was observed between avutometinib (VS-6766, a small molecule MEK/pRAF inhibitor) and defactinib (VS-6063, a small molecule adenosine 5’-triphosphate (ATP) competitive, reversible FAK inhibitor) in KRAS G12V mutant cell lines, in effect, supporting the phase II study evaluating this drug combination for the treatment of recurrent NSCLC with KRAS G12V or other KRAS mutation (NCT04620330) [199]. Here, MAP2K7 is linked to non-small cell lung carcinoma.